Epigenomic?s AG Announces 2013 Third Quarter and 9-Month Financial Results and Reports on Operationa?l Highlights
Epigenomics AG, the German–American cancer molecular diagnostics company, has announced its financial results for the third quarter and the 9 months ending 30 September 2013.
• 9M 2013 revenue increased by 43% to EUR 961 thousand
• 9M 2013 operating costs decreased by 40% to EUR 6.6 million
• 9M 2013 EBIT improved by 45% to EUR -5.2 million
• Strategic partnerships with Polymedco for the US and BioChain for China (after period-end)
• Successful financing of EUR 5.2 million closed (thereof EUR 4.7 million after period-end)
• Supervisory Board re-appoints Thomas Taapken as CEO/CFO until end of 2015.
“In the past weeks we have achieved significant progress as evidenced by two strategically important collaborations we entered into with Polymedco and BioChain and by securing a EUR 5.2 million financing for the future development of our company. We are especially proud that both of our new partners, BioChain and Polymedco, have expressed their commitment and trust in Epigenomics by becoming strategic investors,, said Thomas Taapken, CEO/CFO of Epigenomics AG.
“Investor confidence in Epigenomics finally seems to be returning; our share price has tripled since the beginning of this year. We are committed to live up to these high expectations to the benefit of our shareholders and partners and remain confident to receive FDA approval for Epi proColon in the near future.”
Click here for the full 2013 Third Quarter and 9-Month Financial Report
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance